Zura Bio (NASDAQ:ZURA – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Zura Bio and MiNK Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zura Bio | N/A | -55.74% | -48.07% |
| MiNK Therapeutics | N/A | N/A | -118.57% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zura Bio | N/A | N/A | -$99.35 million | ($1.09) | -3.94 |
| MiNK Therapeutics | N/A | N/A | -$12.49 million | ($2.84) | -4.34 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Zura Bio has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Zura Bio and MiNK Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zura Bio | 1 | 1 | 3 | 1 | 2.67 |
| MiNK Therapeutics | 1 | 2 | 1 | 1 | 2.40 |
Zura Bio currently has a consensus price target of $10.75, suggesting a potential upside of 150.00%. MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 183.86%. Given MiNK Therapeutics’ higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Zura Bio.
Summary
Zura Bio beats MiNK Therapeutics on 6 of the 11 factors compared between the two stocks.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
